MDT Stock Recent News

Medtronic investors have suffered a massive battering as MDT moves closer to its COVID lows. The company's headwinds are likely still manifesting, worsened by macroeconomic challenges.

Medtronic PLC ( MDT , Financial) once again ranked as the number one medical device company in the world in terms of revenue in 2022, according to a study by Proclinical. Moreover, Proclinical estimates that the medical device industry was worth $488.98 billion in 2021 and projects that it could reach a value of $718.92 billion by 2029, representing a significant runway for growth.

During periods of market weakness, such as in 2022, healthcare stocks tend to outperform the broader market. This is owed to the group's relative stability when it comes to revenue and earnings, which also translates to their ability to pay dividends irrespective of economic conditions.

Medtronic is dividend aristocrat, with 45 straight years of payout increases. But shares in the company, a top maker of medical devices, haven't been regal performers.

As COVID-19 headwinds fade, AngioDynamics' business could rebound.

This medtech company is among the most dominant in the world.

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

This medical technology-focused stock offers income investors a 3.6% dividend yield.

We believe that Abbott stock and Medtronic stock in the medical devices industry will likely give similar returns over the next three years. Although Abbott is trading at a higher valuation of 4.2x trailing revenues, compared to 3.

Medtronic's Hugo RAS system is designed to be used in Expand URO U.S. clinical trial study for urologic surgical procedures.